Johnson & Johnson Announces $1 Billion Cell Therapy Manufacturing Plant in Pennsylvania
核心洞察
Johnson & Johnson will invest over $1 billion to build a next-generation cell therapy (搜索) manufacturing facility in Lower Gwynedd, Montgomery County, Pennsylvania, scheduled to open in 2031.
The facility will create more than 500 bio-manufacturing jobs and will produce cutting-edge medicines for cancer (搜索), immune-mediated, and neurological diseases (搜索).
This investment is part of Johnson & Johnson's $55 billion commitment to U.S. manufacturing, research and development through early 2029, aimed at bringing advanced medicine production back to America.
Johnson & Johnson announced plans to build a $1 billion-plus next-generation cell therapy (搜索) manufacturing facility in Lower Gwynedd, Montgomery County, Pennsylvania, marking a significant expansion of the pharmaceutical giant's U.S. manufacturing footprint. The facility, operated under Johnson & Johnson's Janssen BioTech (搜索) division, is scheduled to open in 2031 and will create more than 500 bio-manufacturing jobs.
Strategic Investment in Advanced Therapeutics
The new plant will focus on manufacturing transformational medicines for cancer (搜索), immune-mediated, and neurological diseases (搜索). According to Johnson & Johnson CEO Joaquin Duato, the facility "will advance the company's industry leading portfolio and pipeline of transformational medicines" while increasing the company's already significant presence in Pennsylvania.
Cell therapy (搜索) represents a cutting-edge approach to treatment that involves introducing specific cell types into patients to treat or prevent disease. As reported in the trade journal BioSpace, major pharmaceutical companies like Johnson & Johnson are increasing investments in these complex technologies as other product patents approach expiration.
Part of Broader Manufacturing Strategy
This Pennsylvania investment represents one component of Johnson & Johnson's previously announced $55 billion commitment to U.S. manufacturing, research and development, and technology through early 2029. The initiative aligns with broader pharmaceutical industry efforts to bring drug manufacturing back to the United States as part of agreements with the Trump Administration for tariff relief.
"Our goal is that, at the completion of our investment plan, essentially all the advanced medicines that are used in the U.S. will be manufactured here in the U.S.," Duato stated at the 2026 J.P. Morgan Healthcare Conference. "It's great for the country. It's great to create jobs. And it's great to create more resiliency in our supply chain."
Pennsylvania's Growing Life Sciences Sector
The Johnson & Johnson announcement follows Eli Lilly & Co.'s January announcement of a $3.5 billion plant in Pennsylvania's Lehigh Valley, demonstrating the state's growing appeal to major pharmaceutical manufacturers. Pennsylvania's life sciences sector employs over 100,000 people across nearly 3,100 companies and world-renowned research institutions.
Johnson & Johnson already maintains a substantial Pennsylvania presence, including research and development hubs in Spring House and Horsham, a manufacturing plant in Malvern, and a major MedTech center in West Chester. The company employs thousands of highly skilled workers across these facilities.
Government Support and Economic Impact
The Shapiro Administration has committed $41 million in tax credits, grants, and workforce training funds to support the project. The facility will also be placed in the state's fast-track permitting program to expedite development.
"We value Johnson & Johnson's long-time partnership here in Pennsylvania, and its decision to reinvest in Montgomery County is another huge win for the Commonwealth," said Rick Siger, secretary of the state Department of Community and Economic Development. "This announcement also sends a clear message that Pennsylvania is competing — and winning — when it comes to attracting world-class life sciences companies."
Over the past five years, Pennsylvania researchers and companies have secured over 10,700 new life sciences patents, ranking fourth nationally. Since taking office, the Shapiro Administration has secured over $35.9 billion in private sector investments, creating more than 18,800 jobs across the state.